{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:46:28Z","timestamp":1783734388145,"version":"3.55.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>The development of Botox (onabotulinumtoxinA) began in the 1970s as Dr. Scott was attempting to identify an injectable substance that would weaken the extraocular eye muscles in patients with strabismus as an alternative to muscle surgery. This search led to botulinum toxin type A, which was tested and developed over the next 15 years. As botulinum toxin type A moved from an experimental drug to a product in need of licensing by the Food and Drug Administration (FDA), the first manufacturing methods and quality control procedures were developed for Oculinum, the botulinum toxin type A product that would eventually be sold to Allergan and become known as Botox.<\/jats:p>","DOI":"10.1097\/md.0000000000032371","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:00:11Z","timestamp":1690484411000},"page":"e32371","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Early development history of Botox (onabotulinumtoxinA)"],"prefix":"10.1097","volume":"102","author":[{"given":"Alan B.","family":"Scott","sequence":"first","affiliation":[{"name":"Strabismus Research Foundation, San Francisco, CA, USAdeceased"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Honeychurch","sequence":"additional","affiliation":[{"name":"US Naval Hospital Oakland, CA, USAretired"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[{"name":"Allergan\/AbbVie, Irvine, CA, USA"},{"name":"University of California, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20240803","first-page":"924","article-title":"Pharmacologic weakening of extraocular muscles.","volume":"12","author":"Scott","year":"1973","journal-title":"Invest Ophthalmol"},{"key":"R3-20240803","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.","volume":"87","author":"Scott","year":"1980","journal-title":"Ophthalmology"},{"key":"R4-20240803","first-page":"734","article-title":"Botulinum toxin injection of eye muscles to correct strabismus.","volume":"79","author":"Scott","year":"1981","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R5-20240803","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870020402","article-title":"Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.","volume":"2","author":"Brin","year":"1987","journal-title":"Mov Disord"},{"key":"R6-20240803","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","article-title":"Double-blind study of botulinum toxin in spasmodic torticollis.","volume":"2","author":"Tsui","year":"1986","journal-title":"Lancet"},{"key":"R7-20240803","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.410280407","article-title":"Treatment of spasticity with botulinum toxin: a double-blind study.","volume":"28","author":"Snow","year":"1990","journal-title":"Ann Neurol"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mjd.2002.121356","article-title":"A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.","volume":"46","author":"Carruthers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R9-20240803","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.PRS.0000076504.79727.62","article-title":"Botox Glabellar Lines IISG. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.","volume":"112","author":"Carruthers","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"R10-20240803","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/bmj.323.7313.596","article-title":"Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial.","volume":"323","author":"Naumann","year":"2001","journal-title":"BMJ"},{"key":"R11-20240803","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaad.2007.01.009","article-title":"Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.","volume":"56","author":"Lowe","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R12-20240803","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"R13-20240803","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"key":"R14-20240803","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"R16-20240803","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:55:38Z","timestamp":1722736538000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":15,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032371","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}